rumor walgreen want follow familiar buy-out
playbook amerisourc may go along
page full analyst note feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim dec
price data
rate updat
currenc amount express
valuat growth profit
methodolog valu compani
play critic
pharmaceut suppli chain decad come
perspect firm stand premier player believ
possess wide econom moat thank coloss scale
key cogs within pharmaceut
industri mani supply-chain particip depend
upon servic streamlin product distribut
procur anticip robust growth pharmaceut
industri long term provid firm
solid platform continu success
one three
distributor main supplier larg pharmaci outlet
walgreen express script mail order pharmaci firm
highli integr strateg agreement walgreen
suppli retail pharmaci drug inventori includ
gener last aspect key -- suppli higher-margin gener
drug one biggest gener drug retail outlet major
posit profit capit effici invest capit return
cours fiscal firm manag
excel job major contract integr exceed
initi growth profit expect walgreen
partnership believ reflect strong scale leverag
effici gain new highli integr
addit opportun
procur gener inventori alreadi coloss walgreen
boot allianc develop dynam enabl drug
distributor obtain gener inventori lower cost level
firm also major specialti drug distributor
posit favor benefit fastest-grow drug
categori within pharmaceut market
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one three major pharmaceut distributor
 highli effici distribut asset firm activ includ
forecast logist servic firm also wholesal leader within
high-growth specialti distribut nich
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rumor walgreen want follow familiar
buy-out playbook amerisourc may go along
feb wall street journal report walgreen
recent approach acquir
drug distributor remain equiti walgreen
alreadi transact would vertic integr
drug distribut retail pharmaci space within
 fall line strategi walgreen
current manag team execut europ built
allianc boot busi news still press
report believ rumor substanti
past year walgreen partner integr
signific portion oper asset equiti
amerisourc thu total merger seem like next
logic step retail pharmaci particularli given
desir firm leadership vertic integr
busi howev believ amerisourc may
share sentiment assign amerisourc
wide moat rate assign walgreen no-moat
rate believ vertic integr would benefit
walgreen amerisourc accordingli
premium fair valu estim leav
moat rate fair valu estim place given
offici announc either
inform regard moat valuat
analysi walgreen amerisourc pleas
refer recent report healthcar observ
right prescript no-moat retail pharmaci
market sell drug easier said done moati
pharma channel healthcar observ under-valued
valuat growth profit dec
fair valu estim amerisourc
account firm recent acquisit smith
midtier drug distributor solid growth firm
walgreen partnership slight mix shift toward
done excel job drive organ revenu growth
ramp complex walgreen partnership
great effici firm also posit well
within fast-grow specialti drug distribut sector
largest distributor within market
factor drive solid gross dollar growth extend
addit solid revenu growth also anticip
increas capital-manag effici distributor
next sever year result increas
volum -- notabl integr walgreen
partnership amerisourc procur gener drug
suppli walgreen boot allianc develop
partnership obtain gener drug inventori lower
contribut outlook amerisourc confluenc
age popul influx previous uninsur
peopl healthcar market greater use
pharmaceut front-lin treatment provid
platform solid top- bottom-lin growth accordingli
factor five-year revenu compound-annual-growth-rate
averag oper margin explicit forecast
scenario analysi take consider effect
price volatil supplier price pressur pharmaceut
market growth ultim outcom walgreen
partnership bull-cas scenario factor
less price transpar higher profit result
also assum abl exert even
negoti leverag given access
addit factor high-single-digit industri growth
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
spend flow oper major three
pharmaceut distributor domin result
robust sustain econom profit player
estim cardin health
combin market share well
combin dynam slim industri profit keep new
entrant bay new player would tough time
carv enough share effici leverag
distribut asset posit econom profit
dynam solidifi long-term competit posit
major three drug distributor firm also obtain
deep price discount drug manufactur mani
custom acquir dynam
player essenti cogs along
critic massiv distribut oper
amerisourc mean enjoy excel asset effici
unparallel logist expertis driven decent
asset return howev abil effect manag
capit base true driver outsiz return drug
distributor firm produc top-tier asset turn cash
convers inventori manag metric
led outsiz roic -- trend believ last
despit recent drug price volatil associ
headlin risk believ amerisourc stabl
econom moat trend perspect recent
price headwind near-term firm abl
overcom obstacl given entrench posit
within global pharmaceut space demograph
trend skew older expans government-sponsor
healthcar coverag
increas spend
pharmaceut product provid excel long-term
tailwind firm addit amerisourc play
uptak drug usag increas faster initi
expect scenario fair valu estim
increas approxim per share
bear case assum effort bring price
addit assum gener sourc partnership
walgreen advantag
addit discount obtain also assum secular
industri growth driver fail materi par
current expect scenario fair valu
estim decreas per share
moat perspect three major pharmaceut
distributor carv wide econom moat
coloss size unmatch effici give key
critic role among manufactur retail outlet
solidifi long-term outsiz return accord
estim total retail pharmaceut spend
 littl billion major
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
critic role pharmaceut industri main
sourc drug suppli signific portion retail
pharmaci outlet effici distributor drug
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
major pharmaceut
distributor billion annual revenu
size make firm prefer partner among
major drug manufactur mani retail pharmaci
opharmaceut spend continu grow
robustli next decad given demograph
shift expans medic insur
coverag current uninsur
specialti drug spend continu increas
believ distributor opportun captur
valu nich market improv top-
bottom-lin result
oprofit margin razor-thin
make signific price pressur major
effort procur cheaper suppli gener
product partner
walgreen enhanc negoti power
fixed-cost scale partnership fail outlook
futur revenu profit growth take hit
osal volum could take materi hit
feder govern implement scaled-back
healthcar legisl price control
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
amerisourc good financi health
continu prudent capit alloc polici
strong free cash product oper keep
amerisourc solid financi situat long term
main risk face push
greater government control drug price repeal
afford act concert push
mani pharmaceut stakehold institut
govern control drug price scenario
drug distributor could face prospect government-dict
profit addit current legitim
push within congress repeal key provis
certain mandat scale back drug wholesal
would like see lower volum moder headwind
respect posit scale dynam
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
believ stewardship
larg value-cr sharehold oper
execut capit manag benefici
econom profit firm signific distribut
gener sourc partnership agreement walgreen
part agreement enabl
acquir approxim equiti
balanc believ manag made right
strateg move agreement make amerisourcebergen
exclus drug supplier one world largest
retail pharmaci agreement also give
distributor access advantag gener drug
price firm also servic express script mail-ord
contract contract yield lower level
profit roic gain scale effici
econom posit past sever year
manag built amerisourcebergen
powerhous within specialti drug nich dynam
posit firm highli favor competit posit
within fast-grow specialti pharmaceut market
repres date owner name posit common share held report holder issuer
govern pension fund norway global
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
amerisourc report solid quarter
core
pharmaceut distribut busi price instabl
subsid firm leverag recent infrastructur
invest greater distribut effici find
develop highli encourag
reiter wide moat rate fair valu
estim drug wholesal posit manag
state seamlessli onboard new
store walgreen recent acquir
perspect firm prepar execut well
signific increas distribut volum
expect trend remaind acquir rite
aid store transfer next quarter
region pharmaceut distributor januari
start process integr asset
correspond client book oper believ
solid oper move add firm
top-tier distribut asset grow client book
enhanc wide econom moat
provid moder headwind under-perform
amerisourc non-drug wholes
busi particularli major headwind relat
firm drug compound manufactur key
facil close given manufactur concern rais
recent fda inspect manag state
expect fda concern address soon
prepar open facil fiscal second
quarter firm also report experienc higher
oper cost within veterinari distribut busi
believ issu eman busi
highlight concern amerisourc
expans non-core drug wholes market
believ headwind soften come
quarter build increas risk econom profit
dilut under-perform persist
amerisourc seem recov nice price
pressur face fiscal brand inflat
gener deflat expect rang posit
oper environ within small/independ
client segment remain stabl amerisourc report
decreas lost volum contract custom
quarter combin factor effici
distribut oper allow firm produc
disrupt pbm mco wholesal jan
amazon berkshir hathaway jpmorgan
announc jan trio form independ
healthcar compani help control healthcar cost
 -base employe could
potenti given capit clout three partner
believ certain investor underappreci
moati natur healthcar suppli chain
formid competit advantag insul
signific headwind tri break vertic along
chain dynam healthcar market
difficult navig specul amazon
berkshir jp disrupt space leverag
impress capit war chest busi expertis
caus valuat pbm mco drug wholesal
retail pharmaci fall materi believ
stock price creat
opportun investor acquir solid wide-moat firm
discount would highlight express script
cardin particularli good
exact oper structur products/servic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ultim mandat partnership yet
develop partnership tri
sizabl corpor busi without major
chang within healthcar marketplac capit
manag clout three partner undoubtedli
great howev core-compet healthcar
relat take signific time legitim
oper develop addit believ potenti
new partnership would lack scale size provid
effici price power par major
healthcar servic firm especi case given
local densiti necessari obtain decent provid price
sourc joint ventur among retail pharmaci
drug distributor pharmaci benefit manag
combin number employe firm
close million initi may seem like give
partnership signific price power howev even
firm abl leverag entir million-person
employe base would pale comparison larg
healthcar servic firm equival small/mid-
tier insur estim combin number cover
live five major mco approxim
million live three larg pbm million
live respect thu price power new
partnership would garner significantli lower
healthcar servic firm built addit
mani employe trio base intern
hous independ oper like bring
total number one million potenti cover live
regul legal requir need effici
deliv healthcar extrem oner
absolut need consum safeti
would new entrant need compli variou feder
agenc claim regulatori jurisdict healthcar
servic product also countless state
municip foreign agenc licens regulatori
approv would take year new partnership fulli
compliant abl provid full-servic healthcar
servic employe administr work
wait period would also add signific time
regulatori approv process perspect amazon
berkshir jp new entrant healthcar
market would need partner one three larg
pbm one five larg mco order viabl
player within space
overview drug suppli chain would highlight
recent report sell drug easier said done
moati pharma channel analyz potenti
new competit within pharmaceut market
analysi wide moat exist space
report solid quarter ramp rite aid
amerisourc report solid quarter firm seem
recov price pressur past year
reformul distribut network build
effici address increas pharmaceut volum
assum come year result
line expect reiter
fair valu estim wide-moat rate firm
although believ near-term result posit
believ posit long-term fundament
pharmaceut servic space robust buoy
amerisourc next sever year firm also play
critic role pharmaceut industri mani suppli
chain particip depend servic streamlin
product distribut procur believ
combin factor lead outsiz econom
profit next sever decad amerisourc
manag also state current process
invest new distribut facil complet
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
reorgan announc earlier year
effect bifurc compani
two major
oper pharmaceut drug sourc divis
consult anim health divis believ
realign posit bring relat
servic product two prong leadership
perspect realign benefici
long term streamlin structur help unlock
intern synergi give custom easier time
partner firm multipl product and/or
servic also believ enhanc effici
core drug busi allow maxim return
volum recent gain expans
walgreen contract addit rite aid volum
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
